Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Sarepta Therapeutics cuts one-third of its workforce and pauses drug programs after safety concerns over its gene therapy.

flag Sarepta Therapeutics, a biotech firm, is cutting its workforce by around 500 employees, or a third of its staff, and will pause several drug programs to save over $400 million annually. flag This move follows safety concerns over its Duchenne muscular dystrophy gene therapy, Elevidys, after two patient deaths. flag The company will add a black box warning for liver failure risk and is working on a new immune-suppressing regimen for the therapy.

5 Articles